Análisis Argos
LQDA
LQDASin veredicto3 señales de riesgo
Liquidia Corporation · Healthcare
US$ 78.93
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
24/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Sin recompensas destacadas.
Riesgos
!Venta significativa de insiders en el último trimestre.
!Altman Z'' en zona roja (-6.01)
!Beneish M-Score sugiere manipulación (7.46)
VALOR1/6FUTURO6/6PASADO2/6SALUD0/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO6/6PASADO2/6SALUD0/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance frágil
DividendoEl dividendo aún duerme
Score Argos24de 100Sin veredicto
Ingresos▲1500%
US$ 0.2 B
Margen operativo▼96%
-32.5%
Flujo de caja libre▼60%
US$ -0 B
Deuda neta
US$ 0 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 7.0B
P/E—
EV/EBITDA—
FCF yield-0.6%
ROIC-98.8%
Margen operativo-32.5%
Crecim. ingresos+1031.2%/año
Piotroski F5/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

benzinga.com · 29 jun
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
zacks.com · 23 jun
3 Best Low-Beta Stocks to Buy Right Away: LQDA, FLXS & AGX
LQDA, FLXS and AGX screen as low-beta stocks with positive price moves, solid trading volume and company-specific growth drivers amid market fears.
seekingalpha.com · 16 jun
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
fool.com · 15 jun
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
globenewswire.com · 11 jun
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.
gurufocus.com · 8 jun
Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100
On June 08, 2026, Liquidia Corp (LQDA) shares rose 3.4% today, continuing a strong performance within a 52-week range of $11.85 to $66.78. The stock has shown i
globenewswire.com · 8 jun
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.
zacks.com · 5 jun
4 Best Low-Beta Stocks to Buy Right Away: LQDA, CVX, OXY & VLO
Fragile Iran ceasefire keeps stocks volatile. Low-beta picks LQDA, CVX, OXY and VLO show recent gains and solid volume.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.